Exelixis Outperforms Klotho Neurosciences in Financial Metrics Exelixis demonstrated stronger financial performance than Klotho Neurosciences across key metrics, including revenue, profitability, and institutional ownership. With $2.17 billion in revenue and a 24.04% net margin, Exelixis surpasses Klotho’s $1.35 million net income. Institutional investors own 85.3% of Exelixis compared to Klotho’s 20.1%, signaling confidence in Exelixis’ market potential.1